Uncategorized

Alentis Therapeutics today announced that Rizwan Velji has been appointed Chief Business Officer (CBO).

Delix Therapeutics, a clinical-stage neuroscience company developing novel neuroplasticity-promoting therapeutics for psychiatric and neurological disorders, today announced interim results from the Phase 1 trial evaluating DLX-001.

Kaneka Corporation has acquired all shares of Japan Medical Device Technology Co., Ltd., a developer and manufacturer of medical devices, on November 30, 2023, and made it a wholly owned subsidiary.

Camena Bioscience, a synthetic biology company providing genes to the pharmaceutical and biotechnology industries, announced it has appointed Dr Nicola Thompson as Chair of its Board of Directors.

EVONETIX LTD, the company developing semiconductor scale technology to improve access to gene synthesis, announces the signing of a joint development agreement and commercial supply agreement with Analog Devices, Inc., a global semiconductor leader.

Antengene Corporation Limited announced that the Pharmaceutical Administration Bureau of Macau has approved a New Drug Application for XPOVIO®.

Qilu Pharmaceutical presented the latest results of the single-arm, phase II pivotal clinical study for iparomlimab, an innovative Class 1 antibody monotherapy used to treat unresectable or metastatic dMMR/MSI-H solid tumors through a poster presentation at the European Society for Medical Oncology Asia Congress 2023 taken place from December 1-3.

Teva Pharmaceutical Industries Ltd. announces that a post hoc analysis4 of two phase 3 clinical studies presented at the European Headache Congress has shown the effectiveness of the migraine prevention treatment AJOVY® in reducing migraine attacks in patients with migraine and co-morbid obesity.

Sosei Group Corporation, notes its partner Neurocrine Biosciences Inc., a leading neuroscience-focused biopharmaceutical company, has confirmed its plans to evaluate two new muscarinic agonist candidates in Phase 1 first-in-human clinical studies.

Medivir AB, a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announces that the company will present at the Carlsquare Equity Research Investor Day, December 6, 2023.